TNFRSF17 and plasma cell myeloma: Whilst targeting BCMA with monoclonal antibodies has shown some efficacy in killing myeloma cells in vitro, a range of alternate methods of targeting BCMA are in clinical trials and include ADCs, bi-specific T-cell engagers (BiTE) and chimeric antigen–receptor T-cell (CAR-T) conjugates [72].